Evidence map›Paper›PMID 41735198›Full record

ArticleInternational journal of cancer2026

ID3 deficiency alters chromatin accessibility at DSB sites and enhances vulnerability to HDAC inhibition.

Giuditta Della Corte, Hossam Eldesouky, Julia Puchan, Sercan Öz, Elena Everatt, Ashish Goyal, Gianluca Sigismondo, Udo Oppermann, Christoph Plass, Dieter Weichenhan and 1 more

Abstract read
In one paragraph

Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Giuditta Della CorteDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Hossam EldesoukyDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Julia PuchanDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sercan ÖzDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Elena EverattDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Ashish GoyalDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Gianluca SigismondoDivision of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.
Udo OppermannBotnar Research Centre, Oxford Translational Myeloma Centre, University of Oxford, Oxford, UK.
Christoph PlassDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Dieter WeichenhanDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Ali BakrDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID https://orcid.org/0000-0002-6111-0591

Funding

Deutsche Forschungsgemeinschaft 429192355Deutsche Forschungsgemeinschaft 446166464
6 · The paper itself

Abstract

The inhibitor of DNA-binding 3 (ID3) plays a crucial role in DNA double-strand break (DSB) repair. We previously reported that ID3 loss reduced chromatin accessibility at DNA repair gene promoters, yet its exact role in DNA repair via chromatin regulation remains elusive. Using the AID-DIvA cell system with inducible DSBs, we show that ID3 directly regulates chromatin accessibility at DSB sites, as demonstrated by reduced chromatin accessibility and lower H3K27ac levels in ID3-knockout (KO) cells. Loss of ID3 renders cells susceptible to histone deacetylase (HDAC) inhibition, particularly to the Class I HDAC inhibitor, leading to the accumulation of unrepaired DSBs and delayed cell cycle progression. Transcriptome and proteome analyses revealed that HDAC inhibition in ID3-KO cells results in the downregulation of gene sets involved in the regulation of cell cycle and cell division. The synthetic lethality observed between ID3 loss and Class I HDAC inhibition underscores a novel therapeutic vulnerability in ID3-deficient cancers, driven by compounded defects in chromatin remodeling, cell cycle, and DNA repair. Our study provides new insights into the relationship between chromatin regulation and genome stability, with implications for targeted cancer therapies.

Indexed as

ChromatinDNA Breaks, Double-StrandedHistone Deacetylase InhibitorsInhibitor of Differentiation ProteinsAnimalsCell CycleChromatin Assembly and DisassemblyDNA RepairHumansNeoplasm ProteinsChromatinHistone Deacetylase InhibitorsID3 protein, humanInhibitor of Differentiation ProteinsNeoplasm Proteins

Identifiers

PMID41735198
PMCPMC13106931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.